BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

A.P. Rameswara Rao steps in as National President of Bulk Drugs Manufacturers Association of India

19 September 2025 | News

Rameswara Rao has been a key contributor to the growth of Indiaâ??s pharmaceutical industry

The Bulk Drugs Manufacturers Association of India (BDMAI) has announced the unanimous election of Ch. A.P. Rameswara Rao, Chief Promoter & Director of the Rakshit Group of Companies, as its National President.

With over 35 years of expertise in manufacturing Bulk Drugs and APIs, Rameswara Rao has been a key contributor to the growth of India's pharmaceutical industry. A post-graduate in science, he began his career at Vorin Labs (later acquired by Mylan Laboratories), where he pioneered several innovations and was instrumental in the development of Ciprofloxacin HCl.

His entrepreneurial journey began in 1996 with Metrochem Industries, followed by multiple successful ventures including Rakshit Drugs, Sainor Laboratories, and Azico Biophore, among others.

Under his leadership, his group companies now generate a combined turnover exceeding 120Mn USD, employ more than 2000 professionals, and produce a wide portfolio of APIs for both domestic and regulated global markets.

Rameswara Rao is widely respected as a soft-spoken yet firm leader, known for his vision, humility, and decisive approach.

The BDMAI, established in 1991, represents the collective voice of India's bulk drug and API manufacturers. Its objectives include:

- Strengthening India's self-reliance in APIs and reducing import dependency.
- Promoting global quality standards and compliance across the industry.
- Advocating policy reforms with government and regulatory bodies.
- Supporting sustainable growth through innovation, R&D, and environmental responsibility.

His appointment as National President comes at a crucial time, as India works towards consolidating its position as the global pharmacy hub while ensuring affordability, quality, and security of supply in bulk drugs and APIs.